Dr. Li Xiaoyi

Chairman of the Board
Executive Director and CEO

Dr. Li was appointed as the chairman of the Board, an executive Director and the CEO on January 20, 2017. He is mainly responsible for the formulation of the corporate development strategies and direction for our Group as well as overall day-to-day management of our business and operations. Dr. Li Xiaoyi also holds directorship at each subsidiary of our Group since its establishment.

Dr. Li has over 25 years of experience in pharmaceutical research and development as well as management and strategic planning for pharmaceutical companies. Dr. Li founded Lee’s Pharm in 1994 and has been the chief technical officer since then. Dr. Li was appointed as an executive director and the chief executive officer of Lee’s Pharm in September 2003, where he is responsible for the overall operations and management and research and development of Lee’s Pharm. Dr. Li will resign as the chief technical officer, the chief executive officer and executive director of Lee’s Pharm before the Listing.

In addition to his roles in Lee’s Pharm, Dr. Li also has multiple experience in the management and strategic planning for many other pharmaceutical institutions. Since 2014, he has been serving as the vice president of Hong Kong Biotechnology Organization, mainly responsible for developing the biotech industry in Hong Kong. Since March 2016, he has been serving as the president of Guangzhou Pharmaceutical Association (广州药学会), an academic and non-profit social organization formed by pharmaceutical researchers in Guangzhou, where he is mainly responsible for providing industrial insights for developing the pharmaceutical industry in Guangzhou. Dr. Li is also a member of the review committee of Innovation and Technology Fund of Hong Kong Government, a fund supported by the government of Hong Kong to promote and facilitate technology companies.

Dr. Li obtained his Ph.D. in pharmacology from the medicine college of the University of Illinois in the United States in May 1992.

Dr. Li has earned multiple awards and esteemed recognitions. He has been an adjunct professor at the Hong Kong University of Science and Technology since November 2013 and an honorary fellow since June 2016. In August 2018, he was awarded the leading innovation talent (广州创新领军人才) by the Guangzhou government. In January 2018, Dr. Li was appointed as a member of the People’s Political Consultative Conference of Anhui Province in the PRC, and was honored with the 16th World Outstanding Chinese Award (世界杰出华人奖) by the World Chinese Business Investment Foundation (世界华商投资基金会) in August 2018.

Dr. Lau Lit Fui

President and Chief
Operating Officer

Dr. Lau joined our Group in June 2016 and was appointed as president and chief operating officer of our Group on April 1, 2019. He is primarily responsible for overseeing the overall operation of our Group.

Dr. Lau has 23 years of extensive experience in operation management and research and development of new drugs. From August 1998 to January 2008, he worked in the global research and development department of Pfizer Inc., a worldwide leading pharmaceutical company, where his last position was senior principal scientist heading a biology laboratory and supervising technicians in testing drug candidates. From January 2008 to August 2012, Dr. Lau worked as the associate director of the new product and alliance development department of GlaxoSmithKline (China) R&D Co., Ltd., a science-led global healthcare company, where he was responsible for department management and research and development of new drugs treating neurodegenerative diseases. Dr. Lau joined Lee’s Pharm in October 2012 and had been managing the operation and research and development of Lee’s Pharm until April 2016.

Dr. Lau obtained both his bachelor’s degree in science and master degree of philosophy from The Chinese University of Hong Kong in December 1985 and December 1987, respectively, where he was awarded the Wong Siew Chan Scholarship. In December 1993, he obtained his Ph.D. in biochemical science from the University of Connecticut in the United States. He completed his research fellowship in neuroscience at the School of Medicine of John Hopkins University in the United States in August 1998.

Dr. Lau’s outstanding performances have been recognized by several leading corporations. In February 1991, he was granted SmithKline Beecham Student Pharmacology Award by SmithKline Beecham Pharmaceuticals, a company focused on pharmaceuticals, biologics, vaccines, and consumer healthcare. During his employment with Pfizer, Inc., he was granted several awards by the global research & development department of the company, for his leadership, team work spirit and contribution in research and development. In 2014, he was awarded the Medicines for Life Award by UTASIA Inc., a subsidiary of United Therapeutics Corporation, a company mainly focusing on pharmaceutical preparations business. In 2018, Dr. Lau received an award from CVie Therapeutics Co. Ltd., a subsidiary of Lee’s Pharm, for his sustained contribution and commitment.

Ms. Feng Xinyan

CHIEF FINANCIAL OFFICER

Ms. Feng was appointed as the chief financial officer of our Group on December 7, 2020. She is primarily responsible for financial planning and initiatives and investor relations management of our Group.

From 2000 to 2002, she worked as an analyst at McKinsey & Company. From August 2004 to July 2012, she worked at Goldman Sachs (Asia) L.L.C., and successively held various positions. including the executive director. From July 2012 to September 2014, she served as managing director and head of China equity capital markets at Standard Chartered Bank. From September 2014 to August 2018, she served as executive director of strategic business development and investor relations at Global Brands Group Holding Limited, a company whose shares are listed on the Main Board of the Stock Exchange (stock code: 0787). She served as chief financial officer at ACEA Therapeutics, Inc, a company engaged in developing and delivering innovative treatments to life-threatening diseases from April 2019 to November 2019.

Ms. Feng obtained her bachelor’s degree in computer appliance from Fudan University (复旦大学) in Shanghai, China in July 1998. She obtained a master’s degree in computer science from University of Virginia in the United States in August 2000, and a master of business administration degree from the University of Chicago Booth School of Business in the United States in March 2004.

Dr. Albert Tsai Jr.

Chief Medical Officer

Dr. Albert Tsai Jr. joined the Company as the Chief Medical Officer in June 2021 and is primarily responsible for leading the Group to advance its assets through the clinical development process as well as supporting the post approval medical affairs for the Group’s commercial products (e.g. safety, risk management, thought leader relationships). In addition, Dr. Tsai will provide strategic direction for therapeutic indication development, and contribute to the overall corporate strategy and a culture of innovation and excellence.

Dr. Tsai has 20 years of healthcare experience across the spectrum of pharmaceuticals, biotech, medical devices and healthcare consulting, as well as in various country markets including China, US, Japan and Southeast Asia. From 2019 to 2021, he served as the Vice President, Regional Medical Officer of the Asia-Pacific region at PPD Inc., a leading global Contract Research Organization (CRO), responsible for business development and providing medical/scientific product development advisory to biotech companies in Asia. Prior to that, he served as Vice President, Asia Pacific at The Medicines Company Hong Kong (NASDAQ: MDCO) from 2014–2019, where he developed and implemented the Asia expansion strategy for The Medicines Company Hong Kong with a primary focus on establishing their presence in China and Japan. From 1997–2014, he worked in various leading global pharmaceutical companies including Bayer Schering Pharma AG, Merck Sharp & Dohme (Asia) Ltd., Amgen Inc. and GE Healthcare Inc. in senior medical positions.

Dr. Tsai obtained his Doctor of Medicine (MD) from Northwestern University and Master of Business Administration: Strategy and Finance (MBA) from University of Southern California.

Dr. Li Lok Yee Mandy

Senior Vice President, R&D

Dr. Li joined Lee' s Pharm February 2014, and further promoted to a senior vice president of Lee’s Pharm, leading and managing Lee's Pharm's research and development center. Dr. Li was appointed as the senior vice president, R&D of our Group on September 1 2020.She is mainly responsible for facilitating the business development and execution of scientific strategies of research and project management (including both in-licensed and in-house developed pipeline products) of our Group.

Dr. Li obtained her bachelor of science degree in biochemistry and her Ph.D. in biochemistry from The Chinese University of Hong Kong, in December 2000 and December 2004, respectively. From 2004 to 2006, Dr. Li worked as a research associate at the department of chemical pathology of The Chinese University of Hong Kong. From 2006 to 2007, she worked as a post-doctoral fellow at the department of surgery of The University of Hong Kong. From October 2007 to April 2010, Dr. Li served as a research scientist of Bio-Cancer Treatment International Limited, a Hong Kong company focused on the research and development of innovative anticancer drugs, where she led a research team to conduct research on innovative anti-cancer, playing an active role in responding to FDA queries.

Mr.Mauro Bove

senior vice president
corporate and business development director

Mr. Bove was appointed as the senior vice president, corporate and business development director of our Group on January 1, 2019. He is mainly responsible for overseeing business development activities and identifying new business opportunities and finalizing the relevant negotiations on a global basis.

Mr. Bove has almost 40 years of business and management experience within the pharmaceutical industry working in Europe, North America and Asia. Mr. Bove led for many years until March 2014 the corporate and business development of Sigma-Tau Finanziaria S.p.A.

From May 2005 to December 2014, he served as a non-executive director of Lee’s Pharm. From December 2014 to December 2018, he served as the senior vice president of corporate and business development department of Lee’s Pharm, overseeing the business development activities and identifying new business opportunities for the group.

Mr. Bove obtained his law degree from the University of Parma in Italy in July 1980. In 1985, he attended the Academy of American and International Law at International and Comparative Law Center in Texas, the United States.

Ms. Yau Suk Yan

Financial Controller
and Company Secretary

Ms. Yau was appointed as the financial controller and the company secretary of our Company on September 9, 2019. She is responsible for management and supervision of auditing, report analysis and budget control of our Group.

From September 2004 to January 2010, Ms. Yau served as a manager at KPMG. From February 2010 to July 2015, she was the financial controller and company secretary of Active Group Holdings Limited, currently known as Sino Energy International Limited (中能国际控股集团有限公司), a company whose shares are listed on the Main Board of the Stock Exchange (stock code: 1096), where she was in charge of finance management and audit of the group. From July 2015 to September 2019, Ms. Yau served as the financial controller and company secretary of Uni-Bio Science Group Limited (联康生物科技集团), a company whose shares are listed on the Main Board of Stock Exchange (stock code: 690), where she was responsible for finance management and audit of the group.

Ms. Yau obtained her bachelor’s degree of arts (with honors) in accountancy from the Hong Kong Polytechnic University in November 2004 and completed the CPA qualification programme and passed the professional examination for membership admission and was issued with a practicing certificate by Hong Kong Institute of Certified Public Accountants in August 2006. She has been a certified public accountant of the Hong Kong Institute of Certified Public Accountants since January 2008 and a fellow member of the Hong Kong Institute of Certified Public Accountants since March 2016.

Dr. Samir
Chandrakant Patel

Strategy Consultant

Dr. Patel was engaged by our Company as strategy consultant of our Group on April 9, 2020, to provide our Group with consulting services in relation to, among others, planning business strategies, sourcing business development opportunities, and providing protocol inputs and clinical development integration inputs.

Dr. Patel has over thirty years of extensive experience in ophthalmology, including 10 years in academic medicine and 20 years in the ophthalmic pharmaceutical industry. He obtained his degree of doctor of medicine from the medical school of University of Massachusetts in the United States in 1985 and completed his residency in ophthalmology at the University of Chicago in 1990. Further, Dr. Patel completed his clinical retinal fellowship at the Massachusetts Eye and Ear Infirmary at the Harvard Medical School, being the primary teaching hospital of Harvard Ophthalmology. Dr. Patel was duly elected as a fellow by the American Academy of Ophthalmology in 1992. Dr. Patel commenced his practice in academic ophthalmology at the University of Chicago in 1992 where he eventually served as an associate professor of ophthalmology and the director of retina service, until July 2000.

Dr. Patel further gained valuable insights and experience in the management and operation of pharmaceutical companies since 2000 when he first started his own business by co-founding Eyetech Pharmaceuticals, Inc., a biopharmaceutical company specializing in novel therapeutics to treat eye diseases, where he served as a director and chief of clinical and commercial strategy. In 2007, Dr. Patel co-founded Ophthotech Corporation, a biopharmaceutical company listed on the NASDAQ under the ticker symbol “OPHT” and specializing in the development of novel therapeutics to treat ophthalmic diseases (currently known as IVERIC bio, Inc. and listed on the NASDAQ Global Select Market under the ticker symbol “ISEE”), and served as the company’s founding CEO, president and vice chairman of its board of directors.

Dr. Kwok
Kwan Ho

Consultant

Dr. Kwok Kwan Ho, Alvin is a Consultant at Zhaoke Ophthalmology, he advises Zhaoke on a variety of matters including design of clinical trials, screening of new drug and product candidates, assessment of in-license opportunities, and discussion of general business development and commercial strategies. In addition, he promotes ongoing dialogs b/w Chinese ophthalmologists and leading experts in HK and US/Europe.

Dr. Kwok has practiced ophthalmology for over 30 years. He was the President, the Hong Kong Ophthalmological Society (2005-2009) and currently the Editor-in-Chief, the Hong Kong Journal of Ophthalmology, the official journal of the College of Ophthalmologists of Hong Kong, the Hong Kong Academy of Medicine. Dr. Kwok earned 3 postgraduate doctoral degrees in ophthalmology, and published over 130 papers in indexed journals, and 1 book chapter. He received the Achievement Award, American Academy of Ophthalmology (2014); the Distinguished Service Award, Asia Pacific Academy of Ophthalmology (2008); and the First Runner-up of AFV Best Researcher of the Year in Ophthalmology and Visual Sciences, the Chinese University of Hong Kong (2001-2005). Being the Founding Translation Editor, 'Ophthalmology', the official journal of the American Academy of Ophthalmology (2011-2015); and the Founding Translation Editor, British Journal of Ophthalmology (2004-2012), he translated the English journals into simplified Chinese text that are freely available online. He enjoys clinical service, research and teaching. He is currently the Honorary Associate Professor, The Chinese University of Hong Kong; and the Honorary Clinical Associate Professor, The University of Hong Kong.

Dr. Parag
A. Majmudar

Consultant

Parag A. Majmudar, M.D., is the Consultant for Zhaoke Ophthalmology, and part of the senior management team to determine and oversee clinical research and development and help set overall corporate strategy.

Dr. Majmudar brings many years of clinical experience as a practicing ophthalmic surgeon in the United States in his role as President and Chief Medical Officer of Chicago Cornea Consultants, Ltd., as well as Associate Professor of Ophthalmology at Rush Medical College in Chicago, IL USA.

Dr. Majmudar was elected to the Phi Beta Kappa honor society and graduated with a Bachelor of Arts degree from Lehigh University in Bethlehem, Pennsylvania. After receiving his medical degree at the Medical College of Pennsylvania in Philadelphia, where he was a member of the prestigious Alpha Omega Alpha Honor Society, Dr. Majmudar completed his ophthalmology residency at the University of Chicago, serving as chief resident in the Department of Ophthalmology. He followed his residency with a subspecialty fellowship in cornea, external diseases and refractive surgery at Rush University Medical Center in Chicago. An active participant in clinical research activities, Dr. Majmudar is a highly regarded international lecturer and instructor on the subjects of corneal and refractive surgery.

Dr. Majmudar is an active member of the American Society of Cataract and Refractive Surgery as well as the American Academy of Ophthalmology, and he has received the Academy's Achievement Award and Senior Achievement Award. He is the former Chair of the AAO Refractive Surgery Program Committee, and is a former member of the ASCRS Refractive Surgery Clinical Committee. He serves on the International Council of the International Society of Refractive Surgery, and recently received an ISRS Achievement Award. He is the recipient of the 2020 Eversight “Gift of Sight” Award.

Dr. Majmudar also has a strong interest in venture capital growth opportunities within Ophthalmology and is a founding member of the Visionary Venture Fund, as well as a Scientific Advisor for InFocus Capital Partners. He also serves on the Medical Advisory Board of Med1Ventures.